JP2021503954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503954A5 JP2021503954A5 JP2020545880A JP2020545880A JP2021503954A5 JP 2021503954 A5 JP2021503954 A5 JP 2021503954A5 JP 2020545880 A JP2020545880 A JP 2020545880A JP 2020545880 A JP2020545880 A JP 2020545880A JP 2021503954 A5 JP2021503954 A5 JP 2021503954A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer
- cell line
- cells
- line according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203649.3 | 2017-11-24 | ||
| EP17203649 | 2017-11-24 | ||
| PCT/EP2018/082556 WO2019101998A1 (en) | 2017-11-24 | 2018-11-26 | Modified natural killer cells and natural killer cell lines targetting tumour cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021503954A JP2021503954A (ja) | 2021-02-15 |
| JP2021503954A5 true JP2021503954A5 (https=) | 2022-01-11 |
Family
ID=60569602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545880A Pending JP2021503954A (ja) | 2017-11-24 | 2018-11-26 | 腫瘍細胞を標的とする改変されたナチュラルキラー細胞およびナチュラルキラー細胞株 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200392458A1 (https=) |
| EP (1) | EP3714040A1 (https=) |
| JP (1) | JP2021503954A (https=) |
| CN (1) | CN111788301A (https=) |
| WO (1) | WO2019101998A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6974681B2 (ja) * | 2015-07-29 | 2021-12-01 | オーエヌケー セラピューティクス リミテッド | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| EP4491235A3 (en) | 2019-11-26 | 2025-03-26 | ImmunityBio, Inc. | Primary nk car constructs and methods |
| AU2021286655A1 (en) * | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| JP2024522756A (ja) | 2021-06-18 | 2024-06-21 | オーエヌケイ セラピューティクス リミテッド | ダブルノックアウトナチュラルキラー細胞 |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| JP2025536042A (ja) | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| CN120242073A (zh) * | 2025-03-26 | 2025-07-04 | 遵义医科大学珠海校区 | 一种纳米药物组合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007304590A1 (en) | 2006-10-04 | 2008-04-10 | Cancer Research Technology Limited | Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| EP3307876B1 (en) | 2015-06-10 | 2023-09-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| JP6974681B2 (ja) | 2015-07-29 | 2021-12-01 | オーエヌケー セラピューティクス リミテッド | 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株 |
| WO2017040529A1 (en) * | 2015-08-31 | 2017-03-09 | Bluebird Bio, Inc. | Anti-sialyl tn chimeric antigen receptors |
| US20190134095A1 (en) * | 2016-05-02 | 2019-05-09 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
-
2018
- 2018-11-26 WO PCT/EP2018/082556 patent/WO2019101998A1/en not_active Ceased
- 2018-11-26 US US16/766,652 patent/US20200392458A1/en not_active Abandoned
- 2018-11-26 CN CN201880075232.XA patent/CN111788301A/zh active Pending
- 2018-11-26 JP JP2020545880A patent/JP2021503954A/ja active Pending
- 2018-11-26 EP EP18811771.7A patent/EP3714040A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503954A5 (https=) | ||
| Agustoni et al. | EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis | |
| Modak et al. | Rituximab therapy of lymphoma is enhanced by orally administered (1→ 3),(1→ 4)-D-β-glucan | |
| Gelderman et al. | Complement function in mAb-mediated cancer immunotherapy | |
| Illidge et al. | Obinutuzumab in hematologic malignancies: lessons learned to date | |
| JP2016516800A (ja) | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 | |
| Abou Dalle et al. | Bi-and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives | |
| JP2018522592A5 (https=) | ||
| Sun et al. | CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies | |
| JP2018519327A5 (https=) | ||
| Krupka et al. | Targeting CD157 in AML using a novel, Fc-engineered antibody construct | |
| Bertino et al. | A phase I trial to evaluate antibody-dependent cellular cytotoxicity of cetuximab and lenalidomide in advanced colorectal and head and neck cancer | |
| FI3866850T3 (fi) | Melanooman yhdistelmähoito | |
| González-Rodríguez et al. | Lenalidomide and chronic lymphocytic leukemia | |
| Shek et al. | Pharmacogenetics of anticancer monoclonal antibodies | |
| JP2023538115A5 (https=) | ||
| Morabito et al. | Comparative analysis of bispecific antibodies and CAR T‐cell therapy in Follicular lymphoma | |
| Greil et al. | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | |
| Shin et al. | Current developments in NK cell engagers for cancer immunotherapy: focus on CD16A and NKp46 | |
| JP2020500940A5 (https=) | ||
| Weisel | Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date | |
| Merli et al. | Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin’s lymphoma | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| Sriratana et al. | New immunotherapies in oncology treatment and their side effect profiles | |
| Gelderman et al. | Cross‐linking tumor cells with effector cells via CD55 with a bispecific mAb induces β‐glucan‐dependent CR3‐dependent cellular cytotoxicity |